Shilpa Medicare Limited

Shilpa Medicare Limited (SHILPAMED) is a small-cap Healthcare company valued at ₹18,336 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Shilpa Medicare Limited last traded at ₹925, down 3.86% on the day.

Recent developments

On 2026-09-25, Shilpa Medicare reported record revenue and profit for Q1FY27, with the stock having rallied 238% in 2026. On 2026-09-18, the company's shares rose 7.44% after the US FDA inspection at its Hyderabad unit ended with one observation. On 2026-08-05, the company's Q1 results were highlighted in a broader market update, though no specific details were provided.

Financial performance

The company's business is improving, with annual revenue rising 20.1% and annual net profit surging 212.0%. The latest quarter saw revenue jump 45.1% and net profit rise 114.6% compared to the same quarter a year earlier. The net profit margin widened to 15.8% from 6.1% a year ago, while return on equity and return on capital employed remained at 9.4% and 10.9%, respectively.

Valuation multiples

The stock trades at 74.4 times earnings, a premium to the Healthcare median of 32.0, 7.10 times book value. It yields 0.1%.

Things to watch

The stock is 2.8% below its 52-week high. Promoter shares pledged account for 8.73% of promoter holding. Domestic institutional holding fell 0.53 points in the quarter. The company's return on equity is 9.4%, which is lower than the return on capital employed of 10.9%.

Where it stands

Shilpa Medicare Ltd's latest quarter revenue and net profit reached record levels, with both metrics rising sharply compared to the same quarter a year earlier. The stock is 2.8% below its 52-week high, and promoter shares pledged account for 8.73% of promoter holding. The company's return on capital employed is 10.9%, while return on equity is 9.4%.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.